Objective—To compare distributions of survivin among tissues from urinary bladders of dogs with cystitis, transitional cell carcinoma (TCC), or histologically normal urinary bladders.
Sample Population—24 archived and 7 fresh-frozen specimens of urinary bladders from dogs with cystitis.
Procedures—Immunohistochemical analysis of archived tissue specimens was performed to identify survivin protein in the nucleus and cytoplasm of cells by use of polyclonal rabbit anti-survivin antibody. Tissues that contained ≥ 5% immunoreactive cells were considered positive for survivin protein. Reverse-transcription PCR analysis was performed on fresh-frozen tissues to identify survivin mRNA. Data on tissues from dogs with TCC or histologically normal urinary bladders that were obtained during another study were used for statistical comparisons.
Results—Twelve of 24 (50%) cystitic tissues were positive for nuclear survivin, compared with 28 of 41 (68%) TCC tissues and 0 of 46 (0%) normal tissues. Two of 24 (8%) cystitic tissues were positive for cytoplasmic survivin, compared with 7 of 41 (17%) TCC tissues and 17 of 46 (37%) normal tissues. Proportions of specimens that contained nuclear or cytoplasmic survivin were significantly different between cystitic and normal tissues but not between cystitic and TCC tissues. Four of 7 cystitic tissues were positive for survivin mRNA, which was comparable with results for TCC and normal tissues.
Conclusions and Clinical Relevance—Nuclear survivin was detected in TCC and cystitic tissues but not in normal urinary bladder tissues. Additional studies are needed to determine whether nuclear survivin contributes to the development or progression of TCC.
Objective—To characterize the biological behavior and prognostic factors associated with hemangiosarcoma in cats.
Design—Retrospective case series.
Animals—53 cats with hemangiosarcoma.
Procedures—Data were retrieved from a state veterinary diagnostic laboratory, 3 veterinary colleges, and a private practice.
Results—Cutaneous and subcutaneous tumor locations were more common than visceral (abdominal and thoracic) and oral locations. Surgical excision was the primary treatment in 47 cats. Tumor-free surgical margins were more likely in cutaneous than subcutaneous lesions and were associated with longer survival times. Local recurrence was observed in 6 of 12 cats with subcutaneous lesions for which follow-up was available. Metastatic disease was detected in 5 of 13 cats with adequate staging at initial diagnosis. A sixth cat had pulmonary metastases at the time of euthanasia. In 4 of 10 cats with visceral hemangiosarcoma, the diagnosis was made at necropsy or they were euthanized at the time of diagnosis. Adjuvant therapy was uncommonly used. Eighteen of the 21 known deaths or euthanasias were tumor-related. Higher mitotic counts (> 3 in 10 hpfs) were associated with shorter survival times.
Conclusions and Clinical Relevance—Subcutaneous hemangiosarcoma was more biologically aggressive than the cutaneous form and was more likely to recur locally and result in euthanasia or death of the cat. Metastatic potential of the cutaneous and subcutaneous forms may be greater than previously reported. Visceral hemangiosarcoma is associated with a grave prognosis.
Objective—To evaluate the clinical and pathologic
characteristics of mammary duct ectasia in dogs.
Animals—51 dogs with mammary duct ectasia.
Procedure—Information regarding body condition,
history, number and location of affected mammary
glands, appearance of lesions, surgical treatment,
nonsurgical treatment, and evidence of recurrence or
development of mammary neoplasia was obtained
from surveys sent to referring veterinarians. Results
of information from examination of histologic sections
and referring veterinarians were evaluated for all
mammary duct ectasia biopsies performed between
1992 and 1999.
Results—Duct ectasia was the primary diagnosis in
51 of 1,825 (2.8%) mammary biopsy specimens and
comprised 48% of nonneoplastic mammary diseases.
Affected dogs were evenly distributed over a range of
1 to 13 years of age, with a mean age at the time of
diagnosis of 6.1 ± 3.1 years. All dogs were female (31
sexually intact, 20 spayed); 10 of 26 had whelped.
Duct ectasia was described as nodular (26 dogs), cystic
(13), and multiglandular (11) and located in caudal
(31) more often than cranial (14) or middle glands (10).
Ectasia recurred in 3 dogs. One dog had a history of
previously excised mammary adenocarcinoma; another
subsequently developed mammary carcinoma.
Conclusions and Clinical Relevance—Duct ectasia
affected mature, sexually intact and spayed female
dogs over a wide age range. Certain breeds were
affected more commonly than expected. Increased
risk for mammary neoplasia was not evident. Duct
ectasia should be considered as a cause for mammary
enlargement, especially in young dogs or when its
cystic nature is evident. Mastectomy is usually curative,
and neoplasia should be ruled out in dogs with
ectasia. (J Am Vet Med Assoc 2001;218:1303–1307)
Objective—To determine immunoreactivity of matrix
metalloproteinase (MMP)-1, -3, and -13 in cartilaginous
tumors of dogs, correlate expression of MMP
with histologic grade of tumors and clinical outcome
of dogs, and compare MMP immunoreactivity
between chondrosarcomas and chondromas.
Sample Population—Formalin-fixed, paraffin-embedded
tissues obtained from samples of naturally occurring
chondrosarcomas (n = 31) and chondromas (8) of
dogs that were submitted to our veterinary medical
Procedure—Histologic sections from each sample
were stained with H&E and monoclonal antibody to
MMP-1, -3, and -13 by use of an avidin-peroxidase
immunohistochemical technique. For each section, histologic
grade (I, II, or III) and immunohistochemical
expression (0, 1, 2, or 3) were evaluated. Clinical outcome
was obtained from medical records or interviews
with referring veterinarians and scored as a good outcome,
moderate outcome, or poor outcome.
Correlations among variables and differences between
chondrosarcomas and chondromas were analyzed.
Results—Samples from chondrosarcomas had significantly
higher immunoreactivity of MMP-1 and -13,
compared with immunoreactivity in samples from
chondromas. In chondrosarcomas, a significant positive
correlation (r, 0.386) was found between MMP-1
and -13 immunoreactivities, and a significant negative
correlation (r, –0.390) was detected between MMP-3
and -13 immunoreactivities.
Conclusion and Clinical Relevance—A significant
increase in expression of collagenases (MMP-1 and -
13) in chondrosarcomas, compared with expression in
chondromas, suggests that collagenases may play an
important role in tumor progression, and possibly
metastasis, in chondrosarcomas of dogs. (Am J Vet